Exploring artificial intelligence-assisted diagnosis of esophageal squamous cell carcinoma: insights from a clinical trial

Endoscopy 2025; 57(03): 218-219
DOI: 10.1055/a-2466-6331

Editorial

Referring to Nakao E et al. doi: 10.1055/a-2421-3194

Authors

Bing Hu

¹Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, China (Ringgold ID: RIN34753)

References
1 Bray F, Laversanne M, Sung H. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74: 229-263
2 di Pietro M, Canto MI, Fitzgerald RC. Endoscopic management of early adenocarcinoma and squamous cell carcinoma of the esophagus: screening, diagnosis, and therapy. Gastroenterology 2018; 154: 421-436
3 Horie Y, Yoshio T, Aoyama K. et al. Diagnostic outcomes of esophageal cancer by artificial intelligence using convolutional neural networks. Gastrointest Endosc 2019; 89: 25-32
4 Tokai Y, Yoshio T, Aoyama K. et al. Application of artificial intelligence using convolutional neural networks in determining the invasion depth of esophageal squamous cell carcinoma. Esophagus 2020; 17: 250-256
5 Shiroma S, Yoshio T, Kato Y. et al. Ability of artificial intelligence to detect T1 esophageal squamous cell carcinoma from endoscopic videos and the effects of real-time assistance. Sci Rep 2021; 11: 7759
6 Nakao E, Yoshio T, Kato Y. et al. Randomized controlled trial of artificial intelligence diagnostic system in clinical practice to detect esophageal squamous cell carcinoma. Endoscopy 2024;
7 Yuan XL, Liu W, Lin YX. et al. Effect of an artificial intelligence-assisted system on endoscopic diagnosis of superficial oesophageal squamous cell carcinoma and precancerous lesions: a multicentre, tandem, double-blind, randomised controlled trial. Lancet Gastroenterol Hepatol 2024; 9: 34-44